Literature DB >> 25366687

Progression-free survival: helpful biomarker or clinically meaningless end point?

Alan P Venook1, Josep Tabernero2.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25366687     DOI： 10.1200/JCO.2014.57.9557

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

1.  Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study.

Authors:  Joel Lexchin; Tareq Ahmed
Journal:  CMAJ Open       Date:  2015-07-17

2.  Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.

Authors:  Gideon M Blumenthal; Stella W Karuri; Hui Zhang; Lijun Zhang; Sean Khozin; Dickran Kazandjian; Shenghui Tang; Rajeshwari Sridhara; Patricia Keegan; Richard Pazdur
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

3.  Have we given up on a cure for ovarian cancer?

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2015-06       Impact factor: 3.677

4.  Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?

Authors:  Ryan D Nipp; David P Ryan
Journal:  Oncologist       Date:  2015-02-06

5.  Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer.

Authors:  Manasi S Shah; David R Fogelman; Kanwal Pratap Singh Raghav; John V Heymach; Hai T Tran; Zhi-Qin Jiang; Scott Kopetz; Carrie R Daniel
Journal:  Cancer       Date:  2015-05-14       Impact factor: 6.860

Review 6.  First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.

Authors:  Elena Elez; Guillem Argilés; Josep Tabernero
Journal:  Curr Treat Options Oncol       Date:  2015-11

7.  Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen.

Authors:  Seung-Hoon Beom; Jong Gwang Kim; Seung Hyuk Baik; Seong Hoon Shin; Inkeun Park; Young Suk Park; Myung-Ah Lee; Soohyeon Lee; So-Yeon Jeon; Sae-Won Han; Myoung Hee Kang; Jisu Oh; Jin Soo Kim; Jin Young Kim; Mi Sun Ahn; Dae Young Zang; Byung-Noe Bae; Hong Jae Jo; Hee Kyung Kim; Jung-Han Kim; Ji Ae Yoon; Dong Han Kim
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-27       Impact factor: 4.553

8.  Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors.

Authors:  Monica Ter-Minassian; Sui Zhang; Nichole V Brooks; Lauren K Brais; Jennifer A Chan; David C Christiani; Xihong Lin; Sylvie Gabriel; Jérôme Dinet; Matthew H Kulke
Journal:  Oncologist       Date:  2017-02-08

9.  Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis.

Authors:  Katrin M Sjoquist; Sarah J Lord; Michael L Friedlander; Robert John Simes; Ian C Marschner; Chee Khoon Lee
Journal:  Ther Adv Med Oncol       Date:  2018-08-06       Impact factor: 8.168

10.  Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy.

Authors:  Toshikazu Moriwaki; Yoshiyuki Yamamoto; Masahiko Gosho; Mariko Kobayashi; Akinori Sugaya; Takeshi Yamada; Shinji Endo; Ichinosuke Hyodo
Journal:  Br J Cancer       Date:  2016-03-31       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.